In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to have worsening mental illness. The study involved a national cohort of 95,490 people diagnosed with depression or anxiety disorder, who also were treated with any diabetes drug (apart from insulin).

In one fell swoop March 16, a U.S. federal judge stayed the CDC’s January memo revising the childhood vaccine schedule and the Advisory Committee on Immunization Practices (ACIP) as reconstituted by Health and Human Services Secretary Robert Kennedy, along with everything that committee has done since early June.

Med-tech M&A activity totaled $18.2 billion in January and February 2026, marking one of the stronger openings in recent years.

Biopharma deal value reached $61.17 billion in the first two months of 2026, roughly a 60% increase from the $38.11 billion logged in the same period of 2025 and marking the strongest early year total in BioWorld’s records. The surge was driven by unusually strong activity in both months, with $31.16 billion in January and $30.01 billion in February.

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things hampering psychiatric drug development. “We are still fully reliant on descriptive diagnoses that yield heterogeneous patient cohorts,” Steve Hyman told the audience at the European Congress of Neuropsychopharmacology (ECNP) Roadmap Meeting on Precision Psychiatry in Amsterdam in January.

The BioWorld Neurological Diseases Index (BNDI) finished 2025 up 6.33%, continuing the gains seen through November (closing up 2.64%), after reaching a low in July when it was down 22.48%. By comparison, the Nasdaq Biotechnology Index (NBI) ended the year up 32.4%, while the Dow Jones Industrial Average (DJIA) rose 12.97%. In the first two months of 2026, the BNDI slipped 1.24%, compared with gains of 5.85% for the NBI and 1.9% for the DJIA.

Twelve years on from the World Health Organization formally raising the alarm, antimicrobial resistance continues to grow, and despite numerous public and private incentives and initiatives, the pipeline of antibiotics in development is thinner than ever.